icatibant sold brand name firazyr medication symptomatic treatment acute attacks hereditary angioedema hae adults effective angioedema caused medication ace inhibitor peptidomimetic consisting ten amino acids selective specific antagonist bradykinin receptors bradykinin peptidebased hormone formed locally tissues often response trauma increases vessel permeability dilates blood vessels causes smooth muscle cells contract bradykinin plays important role mediator pain surplus bradykinin responsible typical symptoms inflammation swelling redness overheating pain symptoms mediated activation bradykinin receptors icatibant acts bradykinin inhibitor blocking binding native bradykinin bradykinin receptor little known effects icatibant bradykinin receptor icatibant received orphan drug status australia eu switzerland us treatment hereditary angioedema eu approval european commission july allows jerini market firazyr european unions member states well switzerland liechtenstein iceland making first product approved eu countries treatment us drug granted fda approval august httpsenwikipediaorgwikiicatibant